Clinical trial
Dose Response Study in Japanese Patients
NCT00261417 · AstraZeneca, Industry · Terminated
Key facts
| NCT number | NCT00261417 |
|---|---|
| Title | Dose Response Study in Japanese Patients |
| Official title | A Randomized, Double-Blind, Multicentre, Placebo-Controlled Study to Evaluate the Efficacy, Dose-Response and Safety of Tesaglitazar Therapy in Japanese Subjects With Type 2 Diabetes |
| Lead sponsor | AstraZeneca, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Type 2 Diabetes |
| Intervention type | Drug |
| Interventions | Tesaglitazar |
| Enrollment | 250 |
| Start date | May 1, 2004 |
| Completion | Oct 1, 2005 |
| First posted | Dec 5, 2005 |
| Last update posted | Apr 22, 2009 |
| Countries | Japan |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: